Ceftazidime-avibactam combination therapy versus monotherapy for treating carbapenem-resistant gram-negative infection: a systemic review and meta-analysis
Infection · 2024-10 · 52 (5) · 2029-2042
DOI: 10.1007/s15010-024-02277-y ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Infection, online erschienen am 13.05.2024. Verfasst von Wei Hsu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Hospital Medicine, Chi Mei Medical Center, Tainan, Taiwan. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Azabicyclo Compounds, Carbapenems, Ceftazidime. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 55 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: This meta-analysis was conducted to compare the efficacy of ceftazidime-avibactam combination therapy with that of monotherapy in the treatment of carbapenem-resistant Gram-negative bacterial (CR-GNB). METHODS: A literature search of PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov was conducted until September 1, 2023. Only studies that compared CZA combination therapy with monotherapy for CR-GNB infections were included. RESULTS: A total of 25 studies (23 retrospective observational studies and 2 prospective studies) involving 2676 patients were included. There was no significant difference in 30-day mortality between the study group receiving combination therapy and the control group receiving monotherapy (risk ratio [RR] 0.91; 95% confidence interval [CI] 0.71-1.18). In addition, no significant differences were observed between the study and the control group in terms of in-hospital mortality (RR 1.00; 95% CI 0.79-1.27), 14-day mortality (RR 1.54; 95% CI 0.24-9.91), 90-day mortality (RR 1.18; 95% CI 0.62-2.22), and clinical cure rate (RR 0.95; 95% CI 0.84-1.08). However, the combination group had a borderline higher microbiological eradication rate than the control group (RR 1.15; 95% CI 1.00-1.32). CONCLUSIONS: Compared to monotherapy, CZA combination therapy did not yield additional clinical benefits. However, combination therapy may be associated with favorable microbiological outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Hospital Medicine, Chi Mei Medical Center, Tainan, Taiwan.
- Department of Neurology, Chi Mei Medical Center, Tainan, Taiwan.
- Department of Intensive Care Medicine, Chi Mei Medical Center, Tainan, Taiwan.
- Department of Internal Medicine, Division of Hospital Medicine, Chi Mei Medical Center, Tainan, Taiwan. cindy.hylai@gmail.com.
- Department of Internal Medicine, Division of Hospital Medicine, Chi Mei Medical Center, Tainan, Taiwan. 8409d1@gmail.com.
Zitieren
APA
Hsu, W., Chuang, M. H., Tsai, W. W., Lai, C. C., Lai, H. Y., & Tang, H. J. (2024). Ceftazidime-avibactam combination therapy versus monotherapy for treating carbapenem-resistant gram-negative infection: a systemic review and meta-analysis. Infection, 52(5), 2029-2042. https://doi.org/10.1007/s15010-024-02277-y
Vancouver
Hsu W, Chuang MH, Tsai WW, Lai CC, Lai HY, Tang HJ. Ceftazidime-avibactam combination therapy versus monotherapy for treating carbapenem-resistant gram-negative infection: a systemic review and meta-analysis. Infection. 2024;52(5):2029-2042. doi:10.1007/s15010-024-02277-y
BibTeX
@article{Hsu2024,
author = {Hsu, Wei and Chuang, Min-Hsiang and Tsai, Wen-Wen and Lai, Chih-Cheng and Lai, Hsin-Yu and Tang, Hung-Jen},
title = {Ceftazidime-avibactam combination therapy versus monotherapy for treating carbapenem-resistant gram-negative infection: a systemic review and meta-analysis},
journal = {Infection},
year = {2024},
volume = {52},
number = {5},
pages = {2029--2042},
doi = {10.1007/s15010-024-02277-y}
}
EUVIMED